WeVote
Log In

Bill

Bill

SB 2336

Relating to the Texas Pharmaceutical Initiative.

89th Legislature (2025) Introduced by Lois Kolkhorst

Texas bill SB 2336 establishes pharmaceutical policy initiatives, likely affecting drug pricing, access, or regulation within the state healthcare system.

Referred to Health & Human Services
#education--higher--institutions&programs(i0223) #governor(i0375) #health--general(i0385) #pharmaceuticalinitiativegoverningboard #texas(v71b9) #retirementsystems--stateemployees(i0727) #retirementsystems--teachers(i0726) #stateagencies #boards&commissions(i0749)
0
WeVote Research Nonpartisan
Bill Summary · SB 2336

Legislative bill overview

SB 2336, the Texas Pharmaceutical Initiative, was recently filed and referred to the Health & Human Services Committee. Without access to the bill's specific text, the precise provisions cannot be detailed, but the title suggests it addresses pharmaceutical policy matters within Texas's healthcare system.

Why this is important

Pharmaceutical policy directly affects drug pricing, access to medications, and healthcare costs for Texas residents. Legislative changes in this area can influence drug availability, insurance coverage, and the state's relationship with pharmaceutical manufacturers and distributors.

Potential points of contention

  • Drug pricing mechanisms – Whether the bill includes price controls, transparency requirements, or negotiation authority could face opposition from pharmaceutical companies or support from consumer advocates
  • Generic vs. brand-name drugs – Provisions affecting generic drug accessibility or interchangeability may conflict with patent protections or manufacturer interests
  • State vs. federal authority – Pharmaceutical regulation involves federal oversight; any state-level provisions must navigate existing FDA and Medicare/Medicaid frameworks

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.